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Abstract 
 
While neuroprotective activities of Humanin peptides have been clearly demonstrated, 
the functional mechanism has not been fully understood. Humanin and a majority of 
Humanin analogs showed a disordered structure at low peptide concentrations and 
aggregation at higher concentrations in aqueous solution at pH 7.0. Here we have 
examined the structure in lipid environments, i.e., in the presence of liposome by circular 
dichroism. Humanin underwent a large structure change into a typical β-sheet structure at 
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neutral pH in the presence liposome made of a negatively charged 1,2-dioleoyl-sn-
glycero-3-phosphoglycerol (DOPG), but not an electrically neutral 1,2-dioleoyl-sn-
glycero-3-phosphatidylcholine (DOPC). As Humanin possesses a positive charge at 
neutral pH, the observed structure changes with DOPG suggest electrostatic binding of 
the peptide with the lipid. No effect of NaCl on the Humanin structure was observed in 
neutral solution and in the presence of DOPC liposome. Increasing temperature resulted 
in changes in the structure due to aggregation. On the other hand, the effects of 
temperature on the Humanin structure showed that it has a relatively stable structure in 
the presence of DOPG liposome independent of the presence of NaCl.  
 
Introduction 
 
One of the biggest challenges in drug discovery and development is to find effective 
treatments for neuronal diseases, including Alzheimer’s disease (AD). Currently, there 
are a very limited number of treatments available for the Alzheimer’s disease [1, 2]. 
Humanin (HN), a 24 amino acid peptide (MAPRGFSCLLLLTSEIDLPVKRRA), was 
discovered as a potential therapeutic agent against AD-related diseases [3-10]. However, 
the neuroprotecive mechanism of HN has been little understood [11]. Several HN binding 
proteins, including cell-surface receptors, have been shown to be involved in HN actions 
[12-17]. The structure that is involved in binding to cellular proteins is also unclear [11]. 
Various structures have been proposed, e.g., disordered at low peptide concentration in 
aqueous buffer solutions, or immunoglobulin-like fold in the presence of trifluoroethanol 
(TFE) or sodium dodecylsulfate (SDS)[18-24]. These reagents are often used to mimic 
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membrane environments, as such a short peptide as HN may require structure changes 
before binding to the target proteins, e.g., cell surface receptors [25]. Here we have 
examined the secondary structure of HN in the presence of liposome, by circular 
dichroism (CD), which more closely mimics the cell surface membrane. The effects of 
NaCl and temperature on the HN structure in solution and in the presence of liposome 
were also investigated 
 
Materials and Methods 
 
Chemicals. HN was obtained from Peptide Institute, Inc. (Osaka, Japan). The purity was 
confirmed by the vendor using amino acid and mass spectrometry analysis. Two lipids, 
1,2-Dioleoyl-sn-glycero-3-phosphocholine (DOPC) and 1,2-dioleoyl-sn-glycero-3-
phosphoglycerol sodium salt (DOPG), were obtained from NOF Corp. (Tokyo, Japan). 
Sodium dihydrogenphosphate dehydrate were from Nacalai Tesque Inc. (Kyoto, Japan). 
NaCl was obtained from Wako Pure Chemical Industries, Ltd. (Osaka, Japan). 
 
Formation of unilamellar liposomes with DOPC and DOPG. Unilamellar liposome 
with DOPC and DOPG were prepared by the lipid extrusion protocol as described by 
previous reports [26, 27]. Briefly, the lipids dissolved in chloroform were placed in a 
round glass vial and subjected to evaporation in a vacuum desiccator over 12 hours to 
remove the solvent. The dry lipid films thus obtained were hydrated with 20 mM sodium 
phosphate buffer, pH 7.0 and vortexed for several seconds. The resulting suspension was 
extruded through a polycarbonate filter (pore size of 200 nm) using a Mini Extruder 
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(Avanti Polar Lipids, Inc., Alabaster, AL), leading to an apparently transparent liposome 
preparation with uniform size. All the process was carried out at room temperature. 
 
Circular Dichroism measurements. Far-UV CD measurements were carried out at 
various temperatures using a Jasco J-720 spectropolarimeter (Tokyo, Japan). HN was first 
dissolved in distilled water for a final concentration of 0.2 mg/ml. The peptide 
concentration was spectrophotometrically determined using the molar extinction 
coefficient of 195 at 257.5 nm. The aqueous peptide solution was then mixed with an 
equal volume of various solutions of interest, in which the CD spectra were to be 
determined. The samples thus prepared were incubated at indicated temperature for a 
sufficient time to reach equilibrium structure: no time dependence was observed. When 
time course was measured, CD measurements were immediately initiated upon arrival at 
37°C. 
 
Results and Discussion 
 
1. In 5 mM sodium phosphate buffer. 
 
We have shown before that HN peptides aggregate less in low phosphate concentration, 
i.e., 5 mM [23]. CD measurements were repeated on 0.1 mg/ml HN in 5 mM phosphate 
buffer, pH 7.0. Fig.1 shows the far-UV CD spectra of HN at 0.1 mg/ml at 25°C as a 
function of phosphate buffer concentration. The results were similar to the previous data 
that the secondary structure of HN is essentially disordered in water and 5 or 10 mM 
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phosphate buffer. There was a slight upper shift in intensity around 200 nm in the 
presence of phosphate buffer, but without changes in spectral shape. Note that the mean 
residue ellipticity was also similar to the previous report, although the peptide 
concentration was determined using phenylalanine absorbance here compared to the 
weight-based measurements in the previous report.  
 
The observed disordered structure has raised a question about the functional structure of 
HN [11]. Many peptide ligands, in particular those for G-protein coupled receptors, have 
been shown to undergo conformational changes at the cell surface membranes [25]. We 
have here tested such a possibility using liposomes. Fig.2 shows the far-UV CD spectra 
of 0.1 mg/ml HN in 5 mM phosphate buffer, pH 7.0, in the presence of 0.17 mM DOPG 
or DOPC. The spectrum in DOPC was nearly identical to the spectrum in 5 mM 
phosphate alone, indicating no apparent effects of DOPC on the HN structure. This result 
means either that HN did not interact with this liposome or that the DOPC-bound HN 
underwent no structural changes. The latter possibility may be less likely, as a large 
structure transition was observed with DOPG (Fig.2). Namely, HN underwent a drastic 
structure change in the presence of DOPG, indicating that HN bound to the liposome, 
leading to a large change in the secondary structure. The structure was typical of β-sheet, 
as observed in antibody fold [18, 19, 28].  
 
2. In 10 mM sodium phosphate buffer. 
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A more physiological phosphate concentration of 10 mM was then used to confirm the 
above results. Fig.3 shows the far-UV CD spectra of 0.1 mg/ml HN at 25°C in various 
solution conditions. The spectra were essentially identical in 10 mM phosphate with and 
without 0.15 M NaCl, corresponding to a disordered structure. DOPC had no apparent 
effects on HN structure independent of the presence of 0.15 M NaCl, similar to the result 
in 5 mM phosphate buffer. Thus, HN underwent no structure changes at 10 mM 
phosphate buffer concentration, by the addition of NaCl and in the presence of DOPC. 
Conversely, a drastic change was observed again with 0.17 mM DOPG. The structural 
features with a negative peak at ~219 nm and a positive peak at ~200 nm were distinctive 
(Fig.3), corresponding primarily to the immunoglobulin-like β-sheet structure [18, 19, 
28]. The structure is reminiscent of that observed in the intermediate concentrations of 
TFE and SDS [24]. At higher concentration of these reagents, the HN structure further 
changed to other structures containing both disordered and β-sheet structures [24]. It thus 
appears that the observed intermediate structure in TFE or SDS might correspond to the 
structure that HN acquires upon binding to the DOPG liposome. The observed 
differences in the HN structure between DOPC and DOPG suggest that the structure and 
the function of HN are affected by the surface property of lipid membrane and hence cell 
types, although no such study has been done to our knowledge. DOPC is electrically 
neutral, while DOPG is negatively charged. Therefore, the structure alteration of HN with 
DOPG suggests that the electrostatic interactions contribute to the binding of HN to this 
liposome. Binding and consequent structure changes do not appear to occur for 
electrically neutral DOPC liposome.  
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Fig.3 also shows the effect of 0.15 M NaCl on the HN structure induced by DOPG 
liposome. Although the spectral shape was largely retained, the magnitude was reduced 
by about half of the intensity in the absence of salt. However, this far-UV CD spectrum 
should be viewed with caution. This sample, i.e., a combination of 0.17 mM DOPG, 0.1 
mg/ml HN and 0.15 M NaCl resulted in turbidity development immediately after sample 
preparation. One of the explanations for the observed turbidity is due to disruption of the 
liposome arising from the addition of 0.15 M NaCl and high external osmolality (no 
NaCl is present inside the liposome). However, this is unlikely as DOPC developed no 
turbidity by the addition of 0.15 M NaCl. It is thus possible that the HN bound to DOPG 
liposome indeed underwent structure changes by the addition 0.15 M NaCl. Another 
possibility cannot be ruled out that aggregation of liposome-bound HN occurred due to 
higher ionic strength and such aggregation has distorted the CD spectrum. 
 
Temperature effects 
 
The effects of temperature on HN structure were examined at 5, 10, 25 and 37°C. Fig.4 
shows the spectra of 0.1 mg/ml HN in 10 mM phosphate buffer, pH 7.0. The spectra were 
essentially identical at 5°C and 10°C. The spectrum began to change at 25°C, as seen in  
decrease at ~220 nm and slight increase at ~200 nm. The spectrum significantly changed 
at 37°C and the upward shift continued with incubation time. The results were similar in 
the presence of 0.17 mM DOPC. As shown in Fig.5, the spectra were identical at 5°C and 
10°C and slightly changed at 25°C in the presence of DOPC. Further change occurred at 
37°C. The structural changes at 37°C in the presence and absence of DOPC had a similar 
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time course, as shown in Fig.6, occurring slowly with incubation time and leveling off 
around 30 min. That is, these results imply that HN in fact did not bind to the DOPC 
liposome and were present in solution phase.  A same conclusion was obtained in the 
presence of 0.15 M NaCl (data not shown). Namely, HN underwent spectral changes with 
temperature in both aqueous solution and DOPC liposome containing 0.15 M NaCl, just 
as seen in the absence of NaCl. Thus, HN does not appear to bind to the DOPC liposome 
regardless of the ionic strength. The observed changes with temperature in the presence 
and absence of liposome or in the presence and absence of NaCl are most likely due to 
aggregation as previously proposed [19, 23]. Such aggregation at 37°C has resulted in 
time dependent changes in CD signals. The small changes observed at 25°C is also most 
likely due to aggregation, although no change with time was observed perhaps due to 
slow kinetics of aggregation. 
 
On the contrary, the DOPG-bound HN was highly stable with change in temperature. The 
CD spectra were essentially independent of the incubation temperature, i.e., the 
immunoglubulin-like fold of HN that occurs upon binding to the DOPG liposome was 
retained at physiological temperature (Fig.7). The same was true in the presence of 0.15 
M NaCl. Fig.8 shows little changes in CD spectrum with temperature. As described in 
Fig.3, however, the addition of 0.15 M NaCl might cause changes in the secondary 
structure of DOPG-bound HN. Thus, although some unknown changes might occur in 
HN structure by the addition of 0.15 M NaCl to the DOPG liposome system, whatever 
the structure that was attained on the liposome, it is also stable with temperature.  
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Biological relevance 
 
It appeared clear that HN undergoes structure change upon binding to negatively charged 
DOPG liposome. It is the first report that HN forms a stable structure on lipid membranes. 
It has been speculated that many short peptides are structurally disordered in solution, but 
undergo structure transition upon binding to lipid membrane and the membrane-bound 
structure is responsible for binding to their cognate receptors [25]. Cell surface receptors 
have been identified for HN to transmit the signal and hence lead to neuroprotection [11-
16]. First question is whether the observed immunoglubulin-like structure is responsible 
for receptor binding. The observed structure of HN in the intermediate TFE or SDS 
concentrations also supports this notion that HN can assume such a stable structure [24]. 
Second question is whether such a short peptide as HN can form a stable structure of β-
sheet. Naturally β-sheet structure is formed when two or more β-strand associate with 
each other. If it occurs with the HN chain, the N-terminus of HN should turn back onto 
the C-terminal region to form anti-parallel packing of the peptide. Even if such a turn 
occurs with a potential strain posed on this short peptide, a question is raised whether 
there is enough length to fold back to form a stable β-sheet in the liposome-bound state. 
Another possibility is that two or more HN peptides associate on the liposome to form a 
stable β-sheet. It has been suggested that HN forms a functional dimer in solution [8], 
which was later ascribed to its tendency to aggregate [11]. We subjected the HN 
sequence, MAPRGFSCLLLLTSEIDLPVKRRA, to various secondary structure 
predication programs, none of which indicated strong turn potentials: note that a strong 
potential for β-sheet structures was clearly predicted in both N- and C-terminal regions. 
  10 
One possible sequence for a turn was found near the N-terminus. However, even if this 
sequence makes a turn, there is not enough length N-terminal to this turn and hence to 
make intra-chain anti-parallel β-sheet structure. Therefore, the observed β-sheet structure 
is more likely accounted for by self-association of HN when bound to the liposome.  
 
Summary 
 
The structure change of HN is schematically illustrated in Fig.9. HN is monomeric at low 
peptide concentration and structurally disordered in solution or in the presence of DOPC 
(shown inside the box). As the ionic strength, temperature or peptide concentration is 
increased, it aggregates as shown by a box arrow. The peptide forms a β-sheet structure 
in the presence of DOPG or at the intermediate concentrations of TFE and SDS and is 
assumed to become a functional dimer. This assumption has to be experimentally 
confirmed. At higher SDS and TFE concentrations, the HN peptide will remain 
monomeric, which also needs to be demonstrated. 
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Figure 1. Far UV CD spectra of 0.1 mg/ml HN at 25 ˚C in aqueous solution. Solid line, 
in water; dotted line, in 5 mM phosphate buffer, pH 7.0; broken line, in 10 mM sodium 
phosphate buffer, pH 7.0. 
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Figure 2. Far UV CD spectra of 0.1 mg/ml HN at 25 ˚C in the presence or absence of 
0.17 mM DOPC or DOPG in 5 mM of sodium phosphate buffer, pH7.0. Solid line, 5 mM 
phosphate buffer; dotted line, DOPC; broken line, DOPG. 
DOPG 
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Figure 3. Far UV CD spectra of 0.1 mg/ml HN at 25 ˚C in the presence or absence of 
0.17 mM DOPC or DOPG in 10 mM of sodium phosphate buffer, pH7.0. Black lines and 
grey lines were taken in the absence and presence of 0.15 M NaCl, respectively. Solid 
line, no lipids; dotted line, DOPC; broken line, DOPG. 
DOPG-1, no NaCl. DOPG-2, in 0.15 M NaCl. 
DOPG-1 
DOPG-2 
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Figure 4. Far UV CD spectra at different temperatures of 0.1 mg/ml HN in 10 mM of 
sodium phosphate buffer, pH 7.0. Solid line, 5 ˚C; dotted line, 10 ˚C; broken line, 25 ˚C; 
gray lines, 37 ˚C. 
Arrow indicates increasing incubation time (see Fig.6 for time course). 
  17 
 
Figure 5. Far UV CD spectra at difference temperatures of 0.1 mg/ml HN in the presence 
of 0.17 mM DOPC in 10 mM of sodium phosphate buffer, pH 7.0. Solid line, 5 ˚C; dotted 
line, 10 ˚C; broken line, 25 ˚C; gray lines, 37 ˚C. 
Arrow indicates increasing incubation time (see Fig.6 for time course).
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Figure 6. Time course of structural change of 0.1 mg/ml HN in the absence and presence 
of 0.17 mM DOPC in 10 mM of sodium phosphate buffer, pH7.0. Black and gray 
symbols were taken in the presence and absence of DOPC. 
CD signal at 200 nm was monitored as a function of temperature. 
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Figure 7. Far UV CD spectra at different temperatures of 0.1 mg/ml HN in the presence 
0.17 mM DOPG in 10 mM of sodium phosphate buffer, pH 7.0. Solid line, 5 ˚C; dotted 
line, 10 ˚C; broken line, 25 ˚C; gray line, 37 ˚C. 
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Figure 8. Far UV CD spectra at different temperatures of 0.1 mg/ml HN in the presence 
of 0.17 mM DOPG with 0.15 M NaCl in 10 mM of sodium phosphate buffer, pH 7.0. 
Solid line, 5 ˚C; dotted line, 10 ˚C; broken line, 25 ˚C; gray line, 37 ˚C. 
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Fig.9 Schematic illustration of structure changes of HN 
Box indicates HN in either solution or in the presence of DOPC. 
Box arrow indicates increasing temperature, ionic strength or peptide concentration. 
